The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
Published version of a preprint
Abstract
Purpose: This phase I, dose-escalation study investigated the recommended dose for expansion (RDE) of siremadlin, a p53–MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers. Patients and Methods: Initial dosing regimens were: 1A (day 1; 21-day cycle; dose 12.5–350 mg) and 2A (days 1–14; 28-day cycle; dose 1–20 mg). Alternative regimens included 1B (days 1 and 8; 28-day cycle) and 2C (days 1–7; 28-day cycle). The primary endpoint was incidence of dose-limiting toxicities (DLT) during cycle 1. Results: Overall, 115 patients with solid tumors and 93 with hematologic malignancies received treatment. DLTs occurred in 8/92 patients with solid tumors and 10/53 patients with hematologic malignancies. In solid tumors, an RDE of 120 mg was defined in 1B. In hematologic tumors, RDEs were defined in 1A: 250 mg, 1B: 120 mg, and 2C: 45 mg. More patients with hematologic malignancies compared with solid tumors experienced grade 3/4 treatment-related adverse events (71% vs. 45%), most commonly resulting from myelosuppression. These were more frequent and severe in patients with hematologic malignancies; 22 patients exhibited tumor lysis syndrome. Overall response rates at the RDEs were 10.3% [95% confidence interval (CI), 2.2–27.4] in solid tumors and 4.2% (95% CI, 0.1–21.1), 20% (95% CI, 4.3–48.1), and 22.2% (95% CI, 8.6–42.3) in acute myeloid leukemia (AML) in 1B, 1A, and 2C, respectively. Conclusions: A common safety profile was identified and preliminary activity was noted, particularly in AML. Comprehensive investigation of dosing regimens yielded recommended doses/regimens for future combination studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other MDM2 inhibitors currently in clinical trials include HDM201,365,366 MK-8242,367–369 BI-907828,370 APG-115,371–373 and milademetan (DS-3032b)374 (Table 1).”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [365]
In the citing paper
“Although the specific interaction sites are unknown, they all induce cell death in a variety of tumor cells, particularly in patients with MDM2 amplification and intact p53 expression.”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [365]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 10×
“Murine double minute-2 (MDM2) is the primary negative regulator of p53 (4, 5).”
BackgroundInfluentialThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 2×
“Murine double minute-2 (MDM2) is the primary negative regulator of p53 (4,5).”
BackgroundThe first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889 · cited 1×
“Increasing p53 activity represents a potential therapeutic target that could offer patients with a range of different tumor types new treatment options (11, 27, 28).”
BackgroundZhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462
Jeay, S., Ferretti, S., Holzer, P., Fuchs, J., Chapeau, E. A., Wartmann, M., Sterker, D., Romanet, V., Murakami, M., Kerr, G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0338 · Cited by 87
Self-citationA distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097
Jeay, S., Gaulis, S., Ferretti, S., Bitter, H., Ito, M., Valat, T., Murakami, M., Ruetz, S., Guthy, D. A., Rynn, C., et al. (2015) · eLife · doi:10.7554/elife.06498 · Cited by 85
Self-citationP53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis
Mahfoudhi, E., Lordier, L., Marty, C., Pan, J., Roy, A., Roy, L., Rameau, P., Abbes, S., Debili, N., Raslova, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7881 · Cited by 53
Research works printed but not linked: 26
- Vogelstein, 2000, Surfing the p53 network, Nature, 408, 307, 10.1038/35042675 · DOI · Paper page
- Pant, 2014, Limiting the power of p53 through the ubiquitin proteasome pathway, Genes Dev, 28, 1739, 10.1101/gad.247452.114 · DOI · Paper page
- Tsvetkov, 2010, Ubiquitin-independent p53 proteasomal degradation, Cell Death Differ, 17, 103, 10.1038/cdd.2009.67 · DOI
- Oliner, 1993, Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53, Nature, 362, 857, 10.1038/362857a0 · DOI · Paper page
- Shadfan, 2012, MDM2 and MDMX: alone and together in regulation of p53, Transl Cancer Res, 1, 88
- Konopleva, 2020, MDM2 inhibition: an important step forward in cancer therapy, Leukemia, 34, 2858, 10.1038/s41375-020-0949-z · DOI · Paper page
- Mascarenhas, 2019, Oral idasanutlin in patients with polycythemia vera, Blood, 134, 525, 10.1182/blood.2018893545 · DOI · Paper page
- Erba, 2019, Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia, Blood Adv, 3, 1939, 10.1182/bloodadvances.2019030916 · DOI · Paper page
- Bauer, 2018, A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L), J Clin Oncol, 36, 11514, 10.1200/JCO.2018.36.15_suppl.11514 · DOI
- Khurana, 2019, MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388), Onco Targets Ther, 12, 2903, 10.2147/OTT.S172315 · DOI · Paper page
- Jeay, 2016, NVP-HDM201: cellular and in vivo profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2, Cancer Res, 76, 1225, 10.1158/1538-7445.AM2016-1225 · DOI
- Ferretti, 2016, Insights into the mechanism of action of NVP-HDM201, a differentiated and versatile next-generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials, Cancer Res, 76, 1224, 10.1158/1538-7445.AM2016-1224 · DOI
- Meille, 2017, Optimization of the dose and schedule of an HDM2 inhibitor NVP-HDM201 in a first-in-human Phase I study using a mechanism-based PK/PD model, Cancer Res, 77, CT154, 10.1158/1538-7445.AM2017-CT154 · DOI
- Neuenschwander, 2008, Critical aspects of the Bayesian approach to phase I cancer trials, Stat Med, 27, 2420, 10.1002/sim.3230 · DOI · Paper page
- Guerreiro, 2021, Translational modeling of anticancer efficacy to predict clinical outcomes in a first-in-human phase 1 study of MDM2 inhibitor HDM201, AAPS J, 23, 28, 10.1208/s12248-020-00551-z · DOI
- Friberg, 2002, Model of chemotherapy-induced myelosuppression with parameter consistency across drugs, J Clin Oncol, 20, 4713, 10.1200/JCO.2002.02.140 · DOI · Paper page
- Meille, 2018, Dosing regimen selection supported by population PKPD model of thrombocytopenia
- Wang, 2010, Targeting p53 for novel anticancer therapy, Transl Oncol, 3, 1, 10.1593/tlo.09250 · DOI · Paper page
- Tisato, 2017, MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer, J Hematol Oncol, 10, 133, 10.1186/s13045-017-0500-5 · DOI · Paper page
- Retout, 2012, Prediction of occurrence of thrombocytopenia to select phase 1b dose and dosing regimen for a selective inhibitor of p53-MDM2 in patients with solid tumors
- Sirvent, 2007, Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR, Am J Surg Pathol, 31, 1476, 10.1097/PAS.0b013e3180581fff · DOI · Paper page
- Weaver, 2009, Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma, Mod Pathol, 22, 66, 10.1038/modpathol.2008.153 · DOI
- Fischer, 2010, Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3, J Clin Oncol, 28, 4339, 10.1200/JCO.2010.28.9678 · DOI · Paper page
- Konopleva, 2016, Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia, Cancer Discov, 6, 1106, 10.1158/2159-8290.CD-16-0313 · DOI · Paper page
- Barbosa, 2019, The role of TP53 in acute myeloid leukemia: challenges and opportunities, Genes Chromosomes Cancer, 58, 875, 10.1002/gcc.22796 · DOI
- Jung, 2016, TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma, Nat Commun, 7, 12609, 10.1038/ncomms12609 · DOI · Paper page
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches
Liu, F., Chen, J., Li, K., Li, H., Zhu, Y., Zhai, Y., Lu, B., Fan, Y., Liu, Z., Chen, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02046-3 · Cited by 326
Zhu, H., Gao, H., Ji, Y., Zhou, Q., Du, Z., Tian, L., Jiang, Y., Yao, K., & Zhou, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01314-3 · Cited by 223
Small-molecule correctors and stabilizers to target p53
Fallatah, M. M. J., Law, F. V., Chow, W. A., & Kaiser, P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.007 · Cited by 44
Metadata
- Authors
- Stein, E. M., DeAngelo, D. J., Chromik, J., Chatterjee, M., Bauer, S., Lin, C.-C., Suarez, C., de Vos, F., Steeghs, N., Cassier, P. A., Tai, D., Kiladjian, J.-J., Yamamoto, N., Mous, R., Esteve, J., Minami, H., Ferretti, S., Guerreiro, N., Meille, C., Radhakrishnan, R., Pereira, B., Mariconti, L., Halilovic, E., Fabre, C., & Carpio, C.
- Affiliations
- 1Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- 2Division of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- 3Department of Medical Oncology, Goethe University Frankfurt, Frankfurt am Main, Germany.
- 4University Hospital of Würzburg, Comprehensive Cancer Center Mainfranken, Translational Oncology, Würzburg, Germany.
- 5Department of Medical Oncology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
- 7National Taiwan University Hospital, Taipei, Taiwan.
- 8Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
- 9Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
- 10Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- 11Léon Bérard Center, Lyon, France.
- 12National Cancer Center Singapore, Singapore.
- 13Université de Paris, Hôpital Saint-Louis, Paris, France.
- 14National Cancer Center Hospital, Tokyo, Japan.
- 15Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands.
- 16Hospital Clinic, IDIBAPS, Barcelona, Spain.
- 17Kobe University Graduate School of Medicine and Hospital, Japan.
- 18Novartis Institutes for BioMedical Research, Basel, Switzerland.
- 19Novartis Healthcare Private Limited, Hyderabad, India.
- 20Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
- 21Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2021-12-02
- Volume
- 28
- Issue
- 5
- Pages
- 870-881
- ISSN
- 1078-0432
- 1557-3265
- Cited by
- 90
- References
- 10
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-21-1295
- The paper
- Stein, E. M., DeAngelo, D. J., Chromik, J., Chatterjee, M., Bauer, S., Lin, C.-C., Suarez, C., de Vos, F., Steeghs, N., Cassier, P. A., Tai, D., Kiladjian, J.-J., Yamamoto, N., Mous, R., Esteve, J., Minami, H., Ferretti, S., Guerreiro, N., Meille, C., . . . Carpio, C. (2022). Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-21-1295
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.